Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$313.55 USD

313.55
338,422

-4.47 (-1.41%)

Updated Jul 23, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Change Healthcare (CHNG) Q1 Earnings Miss, Revenues Beat

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.

DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View

by Zacks Equity Research

DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.

PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.

CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up

by Zacks Equity Research

CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.

Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.

Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up

by Zacks Equity Research

Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.

AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

Earnings Estimates Rising for West Pharmaceutical (WST): Will It Gain?

by Zacks Equity Research

West Pharmaceutical (WST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.

Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up

by Zacks Equity Research

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.

Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.

Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up

by Zacks Equity Research

Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.

Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.

OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.

Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up

by Zacks Equity Research

Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.

Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View

by Zacks Equity Research

Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.

Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.

Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up

by Zacks Equity Research

Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.

Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised

by Zacks Equity Research

Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.

IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up

by Zacks Equity Research

Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.